Introduction
This formal correction addresses a critical nomenclature error in a study originally published in 2016 concerning the antibiotic Xantholipin B. The research focused on the production of this compound by a specific mutant strain, Streptomyces flocculus CGMCC 4.1223 WJN-1, created through the inactivation of the stnR gene.
The Nature of the Error
The primary issue identified in the original publication involves the misidentification of a biological resource used during the experimental phase. Specifically, the authors reported the use of a human cancer cell line designated as "BGC-803" for cytotoxicity testing.
Following external feedback and a subsequent internal audit of laboratory records, it was determined that the cell line used was actually MGC-803, a well-documented human gastric cancer cell line. The discrepancy arose from a typographical or nomenclature error during the preparation of the manuscript.
Context and Discovery
The error was brought to light when researchers and database curators noted that "BGC-803" lacked a formal publication history regarding its establishment. Furthermore, the line was not available in the external cell line repository cited in the original 2016 text. This highlights the vital role of centralized biobanks and external repositories in maintaining the integrity of the scientific record. By providing a standard against which researchers can verify their materials, these institutions facilitate the detection of errors that might otherwise persist in the literature.
Scientific Implications
In the fields of oncology and drug discovery, the precise identity of cell lines is paramount for the reproducibility of results. While this correction changes the name of the substrate used to evaluate the biological activity of Xantholipin B, the authors maintain that it does not invalidate the core findings regarding the compound's production by the stnR inactivation mutant.
The update is as follows:
- Original Text: BGC-803 (Human cancer cell line)
- Corrected Text: MGC-803 (Human gastric cancer cell line)
Conclusion and Best Practices
This correction serves as a reminder of the ongoing challenges associated with cell line misidentification in biomedical research. It underscores the necessity of rigorous authentication protocols, such as Short Tandem Repeat (STR) profiling, and the cross-referencing of cell line identities against established databases like Cellosaurus. The proactive steps taken by the authors and the journal nearly a decade after the original publication demonstrate the self-correcting nature of the scientific process and a commitment to maintaining an accurate historical record.
Summary updated